BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11286841)

  • 21. Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.
    Cutuli B; Petit T; Hoffstetter S; Velten M; Dufour P; Giron C; Lederlin P; Jung GM; Bergerat JP; Maloisel F; Bey P; Oberling F
    Oncol Rep; 1998; 5(6):1513-8. PubMed ID: 9769397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
    Rodriguez MA; Fuller LM; Zimmerman SO; Allen PK; Brown BW; Munsell MF; Hagemeister FB; McLaughlin P; Velasquez WS; Swan F
    Ann Oncol; 1993 Feb; 4(2):125-31. PubMed ID: 8448080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
    Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
    J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
    Conway JL; Connors JM; Tyldesley S; Savage KJ; Campbell BA; Zheng YY; Hamm J; Pickles T
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):35-41. PubMed ID: 27979454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
    van Leeuwen FE; Chorus AM; van den Belt-Dusebout AW; Hagenbeek A; Noyon R; van Kerkhoff EH; Pinedo HM; Somers R
    J Clin Oncol; 1994 May; 12(5):1063-73. PubMed ID: 8164031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
    van Leeuwen FE; Klokman WJ; Hagenbeek A; Noyon R; van den Belt-Dusebout AW; van Kerkhoff EH; van Heerde P; Somers R
    J Clin Oncol; 1994 Feb; 12(2):312-25. PubMed ID: 8113838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
    Swerdlow AJ; Barber JA; Horwich A; Cunningham D; Milan S; Omar RZ
    Br J Cancer; 1997; 75(1):116-23. PubMed ID: 9000608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
    Longo DL; DeVita VT
    Important Adv Oncol; 1992; ():155-65. PubMed ID: 1582671
    [No Abstract]   [Full Text] [Related]  

  • 31. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
    Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subdiaphragmatic Hodgkin's disease: the University of Florida experience.
    Hull MC; Mendenhall NP; Colgan ME
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):161-6. PubMed ID: 11777634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
    Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
    J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second cancer among long-term survivors from Hodgkin's disease.
    Nyandoto P; Muhonen T; Joensuu H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):373-8. PubMed ID: 9788418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
    J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
    Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage).
    Zanini M; Viviani S; Santoro A; Soncini F; Bonfante V; Devizzi L; Villani F; Castellani MR; Negretti E; Zucali R
    Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):813-9. PubMed ID: 7525516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.
    Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second malignant neoplasms in patients with Hodgkin's disease.
    Robinson BA; Colls BM; Fitzharris BM; Atkinson CH
    Aust N Z J Med; 1994 Aug; 24(4):368-73. PubMed ID: 7980232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.